|Home | About | Journals | Submit | Contact Us | Français|
Contributors: KH initiated the study and together with EA and ET designed the original protocol, coordinated the study, and analysed the data. EA and ET conducted the electronic searching and the data abstraction. All the authors (KH, EA, ET, SB, EF, RG, DG, PH, KvH, AH, DO, IS, LT-B) contributed to the revision of the protocol, hand searching of journals, and the writing of the paper, which was initially drafted by KH and ET. EF, PH, AH, KvH, and IS carried out the quality assessments. KH is guarantor for the paper.
Objective: To identify and synthesise the findings from all randomised controlled trials that have examined the effectiveness of treatments of patients who have deliberately harmed themselves.
Design: Systematic review of randomised controlled trials of psychosocial and physical treatments. Studies categorised according to type of treatment. When there was more than one investigation in a particular category a summary odds ratio was estimated with the Mantel-Haenszel method.
Setting: Randomised trials available in electronic databases in 1996, in the Cochrane Controlled Trials Register in 1997, and from hand searching of journals to 1997.
Subjects: Patients who had deliberately harmed themselves shortly before entry into the trials with information on repetition of behaviour. The included trials comprised 2452 randomised participants with outcome data.
Main outcome measure: Repetition of self harm.
Results: 20 trials reported repetition of self harm as an outcome variable, classified into 10 categories. Summary odds ratio (all for comparison with standard aftercare) indicated reduced repetition for problem solving therapy (0.73; 95% confidence interval 0.45 to 1.18) and for provision of an emergency contact card in addition to standard care (0.45; 0.19 to 1.07). The summary odds ratios were 0.83 (0.61 to 1.14) for trials of intensive aftercare plus outreach and 1.19 (0.53 to 2.67) for antidepressant treatment compared with placebo. Significantly reduced rates of further self harm were observed for depot flupenthixol versus placebo in multiple repeaters (0.09; 0.02 to 0.50) and for dialectical behaviour therapy versus standard aftercare (0.24; 0.06 to 0.93).
Conclusion: There remains considerable uncertainty about which forms of psychosocial and physical treatments of patients who harm themselves are most effective. Further larger trials of treatments are needed.
Prevention of suicide is now included in health policy initiatives in several countries, and reduction in suicidal behaviour, both fatal and non-fatal, is part of the Health for All targets of the World Health Organisation.1 In the United Kingdom, reduction in the number of suicides is a central theme in the government’s Health of the Nation strategy for England.2 There is, however, a considerable lack of information as to which preventive strategies are effective.3 Improvement of outcome after deliberate self harm is an important focus because at least 1% of patients presenting to general hospitals in the United Kingdom after deliberate self harm kill themselves within a year and 3-5% do so within 5-10 years. A history of multiple episodes of deliberate self harm is a particular risk factor.4 Higher rates of suicide after deliberate self harm have been reported from other countries.5,6 About half of all people who kill themselves have a history of deliberate self harm, an episode having occurred within the year before death in 20-25%.7,8
It would be difficult to investigate the effectiveness of intervention strategies after deliberate self harm in terms of subsequent actual suicides because extremely large populations of patients would be required. Repetition of deliberate self harm is, however, a reasonable proxy measure because of its strong associations with suicide. It is also in itself an important outcome because it occurs frequently,9,10 indicates persistent distress, and results in considerable healthcare costs. Deliberate self harm is common in Europe11 and in other parts of the world,12,13 especially in young people. Recent marked increases in rates of deliberate self harm in the United Kingdom,14,15 with a currently estimated 140000 hospital referrals in England and Wales,10 have highlighted the need for effective aftercare strategies.
Descriptive reviews of treatment outcomes in patients who deliberately harm themselves have been published previously but have not included systematic screening of the literature, quality ratings, and meta-analysis,16–18 and have been based on heterogeneous groupings of treatments which do not inform clinical practice.19
We conducted a systematic review of the worldwide literature regarding treatment studies of patients who deliberately harm themselves. We identified all randomised controlled trials evaluating psychosocial or physical treatments and conducted a meta-analysis to compare the effects of specific treatments on repetition of deliberate self harm with those of control or comparison treatments to identify the most effective interventions.
—We carried out a literature search using the following electronic databases: Medline 1966 to May 1996; PsycLit 1974 to August 1996; Embase 1980 to November 1996; and the Cochrane Controlled Trials Register (No 4, 1997).20 A wide range of keywords to indicate attempted suicide and a standard search strategy, developed for the Medline database by the Cochrane Collaboration, was used to identify relevant randomised controlled trials. A shorter version of this search strategy was used to perform searches on PsycLit and Embase (details of search strategies available from the authors). In addition, we hand searched 10 journals in the specialty of psychiatry and psychology that had not been searched within the Cochrane Collaboration, including all the English language journals concerned with suicide.
—We included studies in the review if they met the following criteria: study participants had to have engaged in deliberate self harm (self poisoning or self injury) shortly before entry into the trial; trials must have reported repetition of deliberate self harm as an outcome measure; and study participants had to have been randomised to treatment and control groups. As long as these three criteria were met we included papers reporting any comparison between different types of treatment, including comparisons with standard (that is, routine) aftercare. When details of standard aftercare were not provided, we attempted to obtain these from the authors.
—Studies that shared similar treatment strategies were grouped by consensus of the reviewers, blind to the outcome data. The first category (problem solving therapy v standard aftercare) included studies in which participants in the experimental group were offered some form of problem solving therapy which was compared with standard aftercare. Standard aftercare, both here and in other categories, included the usual range of treatment options that were available in routine care at the time in each setting. The second group (intensive intervention plus outreach v standard aftercare) included studies in which the patients in the experimental group had greater access to therapists than in standard care and where efforts were made to keep contact with patients through some form of outreach (for example, home based treatment either as standard or for those patients who defaulted on appointments at a clinic). The third group (emergency card v standard aftercare) included studies in which patients in the experimental group, in addition to being offered standard aftercare, were given an emergency contact card with which they had 24 hour access to emergency advice from a psychiatrist21 or could admit themselves to hospital.22 In only one other group (antidepressant medication v placebo) was there more than one trial. The remainder of the studies are reported singly.
—Data were extracted independently by two reviewers. The quality of the papers was rated by two independent reviewers blind to authorship, according to the recommended Cochrane criteria for quality assessment.23 This rating system is influenced by the finding that the quality of concealment of random allocation can affect the results of trials.24 Studies were assigned a quality score from 1 (poorest quality) to 3 (best quality). Thus, trials rated as inadequately concealed (for example, via alternation or reference to an open random number table) were given a score of 1. Trials that did not give adequate details about how the randomisation procedure was carried out were given a score of 2. Trials that were deemed to have taken adequate measures to conceal allocation (for example, serially numbered, opaque, sealed envelopes; numbered or coded bottles or containers) were given a score of 3. We contacted authors of trials for more information when the concealment of allocation was not clearly reported (that is, when trials were initially in category 2). Blinding of observers was rated according to whether it was absent or unclear, reported but without details, and fully reported.
—Summary odds ratios were calculated with RevMan 3.0 software25 with the Mantel-Haenszel method. Heterogeneity was tested with a χ2 test.
Twenty studies were identified through the combined search strategies as eligible for inclusion in the study. All reports had been published, although two studies had not been published in full.16,26 The full report of one trial was provided by the author in the form of an unpublished manuscript,16 and a detailed report of the other was obtained from conference proceedings.26 Four studies had been reported in more than one publication.16,26–28 One further randomised controlled trial of patients who deliberately harmed themselves was identified, but this did not include repetition of deliberate self harm as an outcome variable.29 We were unable to obtain this information from the authors of this trial.
The trials identified were grouped as described in the methods section. Table Table11 summarises the 20 trials included in the review, their groupings, details of participants (sex and the proportion with a history of self harm—“repeaters”), the interventions used, and the quality of concealment scores. Only one trial was specifically of adolescents.22
The assessment of quality of concealment of allocation (table (table1)1) resulted in 13 trials being given a score of 3 (for adequate concealment), three trials being given a score of 2 (unclear concealment), and four trials being given a score of 1 (inadequate concealment). Blinding of assessors was not stated or was unclear in 12 trials, was indicated but no further details given in seven trials, and was fully reported in one trial.
A total of 2641 patients were randomised in the 20 trials, and outcome data regarding repetition of deliberate self harm during follow up were available for 2452. The results of the individual studies in terms of repetition of deliberate self harm during follow up are shown in table table2.2. Also shown is the number of suicides, when these were reported.
The summary odds ratios for each of the treatment categories that included more than one study are shown in the figure, which also indicates the total number of patients within each category.
—All four studies reported reduced repetition of deliberate self harm in patients in the experimental groups. The summary odds ratio of 0.73 (95% confidence interval 0.45 to 1.18), however, was not significant. It should be noted that the effect size was smallest in the largest trial30 in this category. The trial which involved two forms of problem solving was included here because the control treatment of brief problem solving was standard treatment by the time this study was conducted.33 Omission of this trial, which was also the only one in this category not given the highest rating of quality of concealment of allocation, made little difference to the summary odds ratio (0.78; 0.47 to 1.29).
—There was no consistent direction of effect among studies in this group (see figure). Inclusion of only those trials with the highest quality of concealment of allocation did not greatly alter the summary odds ratio (0.86; 0.60 to 1.23).
—In both studies in this comparison there was a tendency towards less repetition of self harm in the experimental group, but the summary odds ratio 0.45 (0.19 to 1.07) was not significant. The odds ratio was similar when only the results of the trial with the highest quality rating were analysed (0.43; 0.15 to 1.27).
—In this study27 there was a significantly lower rate of repetition of self harm during follow up in patients who received dialectical behaviour therapy (see table table2;2; 0.24; 0.06 to 0.93; number needed to treat=3). This comparison, however, was restricted to a subgroup of randomly assigned patients which was smaller than that which entered the original trial.46
—The small sample size of the single study in this comparison (see table table2)2) precluded meaningful conclusions from the odds ratio analysis (0.60; 0.08 to 4.45).
—The repetition rate in the group of patients who received aftercare from the same person who assessed them in hospital after their initial episode of deliberate self harm was significantly higher than that of patients who had a change of clinician (see table table2;2; 3.70; 1.13 to 12.09). The authors reported, however, that despite randomisation there were several imbalances between the experimental and control groups, resulting in a greater prevalence of risk factors for repetition in the experimental group. It is of note that continuity of therapist resulted in 48/68 (71%) patients attending at least one outpatient treatment session compared with 34/73 (47%) patients in the control group (2.75; 1.37 to 5.52).
—The odds ratio from the one study in this category (see table table2)2) did not indicate a beneficial effect of general hospital admission after deliberate self harm (0.75; 0.16 to 3.60). Only 15% of patients referred, however, were eligible for inclusion in the study as only those attempters at low risk and without immediate medical or psychiatric needs could be considered for discharge without treatment. The follow up period was relatively short.
—There was a significant reduction in repetition of deliberate self harm in patients receiving flupenthixol (see table table2;2; 0.09; 0.02 to 0.50; number needed to treat=2). The trial was relatively small and all the patients were repeaters.
—The summary odds ratio for the two studies in this category (see figure) indicated no apparent benefit regarding repetition of deliberate self harm for patients treated with mianserin or nomifensine compared with placebo (1.19; 0.53 to 2.67).
—There was no indication that long term therapy was more effective in terms of preventing repetition than short term therapy for patients with a history of self harm (see table table2;2; 1.0; 0.35 to 2.86).
The results of this systematic review indicate that currently there is insufficient evidence on which to make firm recommendations about the most effective forms of treatment for patients who have recently deliberately harmed themselves. This is a serious situation given the size of the problem of deliberate self harm throughout the world10–13 and the importance of dealing with the problem to prevent suicide.3
In nearly all trials the subjects were recruited after attendance at a general hospital because of deliberate self harm. Some trials included only patients who had poisoned themselves, who constitute most of the patients who deliberately harm themselves10; others included patients who had poisoned themselves and those who had injured themselves, whereas some did not specify the method of self harm. Most of the studies focused on patients who could be treated as outpatients. Patients who, for example, required psychiatric hospital inpatient care because of severe mental illness or serious risk of suicide, or both, were excluded, but these comprise the minority of patients who harm themselves and who present to general hospitals.10 The studies examined are therefore of relevance to a large proportion of patients who deliberately harm themselves who will be treated in the community. Most patients in the studies had a history of episodes of self harm, and in seven trials the whole sample consisted of such patients.26,27,32,36,42,44 Only one study included only patients with no history of self harm.21 In view of the considerable problem of deliberate self harm in adolescents in many countries11,47 it is surprising that only one trial focused on this specific clinical population.22
The comparison intervention for most of the studies of psychosocial intervention was standard care. In some studies details of this care were not provided, particularly in terms of treatment content. Future studies in which standard care is included should define precisely the nature of the treatment patients received. The dependent variable studied in this review—namely, repetition of self harm—was not consistently defined and measured in a standard way across all studies. In most studies repetition was based on hospital referral for further deliberate self harm, whereas in some studies interviews with patients and other informants also identified episodes of self harm which did not result in hospital referral.
The main problem with nearly all trials in this study is that they included far too few subjects to have the statistical power to detect clinically meaningful differences in rates of repetition of deliberate self harm between experimental and control treatments, if such differences existed. The number needed is a function of both the expected rate of repetition (that is, that in the control group) and the size of the difference. If the predicted rate were 10% in the experimental group versus 15% in the control, with α set at 0.05 and β set at 0.2, 1560 subjects would be required in each treatment group, whereas if the rates were 20% and 30%, 293 subjects would be required in each group.48 Even when the results from similar trials were synthesised with meta-analytical techniques there were insufficient numbers of patients to detect such differences. The only significant findings have come from smaller studies, which may reflect publication bias.49
Promising results were found for problem solving therapy, which is a brief and reasonably easily taught form of treatment.50 Although a clinically insignificant difference was found in the biggest trial,30 a larger trial of this treatment is indicated. There were also trends favouring provision of an emergency access card in addition to standard aftercare but again a larger trial is required, including specific attention to what part the card might play as only a small minority of patients actually used the facility provided by possession of the card.21,22
A larger replicative trial is required of the promising single study of dialectical behaviour therapy (which is similar to cognitive behaviour therapy) in women with borderline personality disorder who have a history of multiple episodes of deliberate self harm.27 As the intervention is intensive,51 development and evaluation of a shorter form of this treatment more suited to provision of general psychiatric services and investigation of its efficacy in men are needed.
The positive result of depot neuroleptic medication in a single small study of patients who repeatedly harm themselves26 suggests that this treatment should be subjected to further evaluation in a larger study, although reluctance of patients to accept depot medication, side effects, and other practical and ethical implications, may limit its applicability. There was little indication that intensive intervention plus outreach was effective. In one relatively large study in this group, which evaluated community follow up of patients who did not attend outpatient appointments,40 there was a significant increase in outpatient attendance from 42.5% before the home visit (39.8% in the control group) to 51.2% after the visit (odds ratio 1.58; 1.15 to 2.33) and a near significant difference in repetition of deliberate self harm of 10.7% compared with 17.4% (0.57; 0.32 to 1.02). Home treatment was also found substantially to increase the rate of take up of treatment in another trial in this review.38 Assertive outreach for poorly compliant patients may, therefore, be a necessary component in maximising the delivery of any treatment that is shown to be effective.
There was no evidence that antidepressants were generally effective in preventing repetition of behaviour in patients who deliberately harm themselves. One of the drugs investigated, however, is no longer available (nomifensine) and the other (mianserin) is now little used. This review does not give any indication of whether other antidepressants could be of benefit.
Repetition of deliberate self harm has been the sole outcome variable investigated in this review. It will be important to determine whether there is evidence of benefits with regard to other outcomes (for example, depression or problem resolution), although the data for these factors, when reported, were often inadequate for meta-analysis. The groups of patients were often heterogeneous in term of sex, age, and presenting problems. Further work in this specialty should examine the efficacy of interventions according to such factors.
At present, evidence is lacking to indicate the most effective forms of treatment for patients who deliberately harm themselves. This is a serious situation given the size of the population at risk and the risks of subsequent self harm, including suicide. Large trials are required of the interventions shown in small trials to be of possible benefit. There is also a need for development of further treatment approaches informed by current knowledge about the psychosocial and biological characteristics of these patients and the socioeconomic and sociocultural context of the behaviour.
This study was carried out under the auspices of the Depression, Anxiety and Neurosis Review Group of the Cochrane Collaboration. Updated versions of the review will appear in the Cochrane Controlled Trials Register in the future. We thank Rachel Churchill and Drs Douglas Altman, Clive Adams, John Geddes, and Henry McQuay for advice. We also thank the several authors who supplied us with unpublished information regarding their trials.
Funding: Anglia and Oxford Research and Development Committee.
Conflict of interest: None.